Last reviewed · How we verify

Sintetica SA — Portfolio Competitive Intelligence Brief

Sintetica SA pipeline: 2 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 3 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hyperbaric Bupivacaine HCl 0.5% Hyperbaric Bupivacaine HCl 0.5% marketed
Chloroprocaine 1% Injectable Solution Chloroprocaine 1% Injectable Solution marketed Local anesthetic (ester) Voltage-gated sodium channels Anesthesia
Chloroprocaine 3% eye gel Chloroprocaine 3% eye gel phase 3 Local anesthetic (ester) Voltage-gated sodium channels Ophthalmology
Chloroprocaine 3% Chloroprocaine 3% phase 3 Local anesthetic (ester) Voltage-gated sodium channels Anesthesia
Chloroprocaine HCl 2% Chloroprocaine HCl 2% phase 3 Local anesthetic (ester) Voltage-gated sodium channels Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Oregon Health and Science University · 2 shared drug classes
  2. Ain Shams University · 1 shared drug class
  3. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  4. American Genomics, LLC · 1 shared drug class
  5. Atlantic Health System · 1 shared drug class
  6. Aultman Health Foundation · 1 shared drug class
  7. Aligarh Muslim University · 1 shared drug class
  8. Ain Shams Maternity Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sintetica SA:

Cite this brief

Drug Landscape (2026). Sintetica SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sintetica-sa. Accessed 2026-06-10.

Related